echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hisun Pharmaceutical's infliximab will be approved soon

    Hisun Pharmaceutical's infliximab will be approved soon

    • Last Update: 2021-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 10, the NMPA official website showed that Hisun Pharmaceutical’s infliximab biosimilar entered the administrative approval stage and is expected to be approved in the near future


    Infliximab is a human-mouse chimeric monoclonal antibody that specifically blocks tumor necrosis factor (TNF-α) developed by Johnson & Johnson / Merck.


    The drug was first approved by the FDA for marketing in the United States in 1998, and was approved for marketing in Europe the following year.


    Although it has been on the market in China for many years, the first infliximab biosimilar was only approved in July this year, from Taizhou Maibotec Pharmaceuticals


    From Insight database (http://db.


    Among several TNF-α antibody drugs, adalimumab has the most fierce competition as the "drug king".


    From Insight database (http://db.


    Biosimilars have not been optimistic about the recent threat of centralized procurement


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.